Rocket Doctor AI

Rocket Doctor AI FCF Conversion

Delisted

The FCF Conversion Rate (FCF/EBITDA) of Rocket Doctor AI (TRUE.CN) as of Nov 16, 2026 is 58.78 %. In the previous year, FCF Conversion Rate (FCF/EBITDA) was 19.88 % — a change of 195.65% (higher).

FCF Conversion

58.78 %

YoY

195.65%

Last updated:

FCF Conversion Rate (FCF/EBITDA) of Rocket Doctor AI is 2024 58.78 % . FCF Conversion Rate (FCF/EBITDA) of Rocket Doctor AI was 2023 19.88 % . It decreases by 195.65% higher compared to the previous year.

The Rocket Doctor AI FCF Conversion history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF Conversion
Date
FCF Conversion
Jan 1, 2017
81.24 CAD
Jan 1, 2018
153.21 CAD
Jan 1, 2019
16.97 CAD
Jan 1, 2020
69.19 CAD
Jan 1, 2021
45.37 CAD
Jan 1, 2022
38.40 CAD
Jan 1, 2023
19.88 CAD
Jan 1, 2024
58.78 CAD
The Rocket Doctor AI FCF Conversion history
YEARFCF ConversionYoY
58.78 %+195.65%
19.88 %-48.23%
38.40 %-15.36%
45.37 %-34.42%
69.19 %+307.77%
16.97 %-88.93%
153.21 %+88.58%
81.24 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Rocket Doctor AI Stock analysis

What does Rocket Doctor AI do? Treatment.com AI Inc generates revenue through its Treatment Digital Health App, a symptom assessment tool developed by a global team of doctors and engineers. The app provides predictive health insights using disease rate estimates, geographic variation data, and medical research, targeting patients and caregivers seeking informed health decisions. The company also offers medical education solutions and clinical advisor services, serving healthcare professionals and institutions globally. Revenue streams include subscriptions for app access and tailored medical education programs. The Treatment Digital Health App is designed for widespread use, offering advanced medical knowledge access to users worldwide. Medical clinic solutions are integrated into the platform, supporting healthcare providers in decision-making. Clinical advisor services leverage the AI platform to assist clinics and institutions with specialized medical guidance. These offerings are marketed to healthcare consumers, clinics, and educational institutions as part of the company's global healthcare technology strategy. Treatment.com AI Inc's business model focuses on AI-driven health solutions, with the Treatment Digital Health App as its primary product. The app's predictive health assessments are updated regularly by medical professionals, ensuring relevance and accuracy. The company monetizes through direct consumer subscriptions and B2B partnerships with medical clinics and educational providers, emphasizing global accessibility and evidence-based medical insights. Rocket Doctor AI is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Rocket Doctor AI stock

FCF Conversion Rate (FCF/EBITDA) of Rocket Doctor AI is 58.78 % in 2024.

FCF Conversion Rate (FCF/EBITDA) of Rocket Doctor AI changed from 19.88 % to 58.78 %, representing a 195.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of FCF Conversion Rate (FCF/EBITDA) Rocket Doctor AI since 2006 – with annual values, charts, and detailed analysis.

FCF conversion measures how effectively EBITDA converts to free cash flow. Higher conversion indicates efficient capital allocation and low maintenance costs.

A 'good' varies by industry and company stage. On Eulerpool, you can compare FCF Conversion Rate (FCF/EBITDA)'s Rocket Doctor AI with sector peers and the industry average to assess whether it is attractive.

To evaluate FCF Conversion Rate (FCF/EBITDA)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for FCF Conversion Rate (FCF/EBITDA).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Rocket Doctor AI

All Key Metrics — Rocket Doctor AI